Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Oral antiviral drugs which can be given to patients with HBeAg-positive chronic hepatitis B include Lamivudine, Clevudine, Adefovir, Telbivudine, Entecavir and Tenofovir. 2009 American Association for the Study of Liver Disease (AASLD) Treatment Guidelines and 2009 European association for the Study of the Liver (EASL) Treatment Guidelines recommend the administration of Entecavir or Tenofovir with high potency and low resistance. Lamivudine has low antiviral potency and high incidence of mutation in long-term administration compared to Entecavir or Tenofovir. Clevudine causes the elevated creatinine kinase (CK), side effects including myositis/myopathy and much mutation in the long-term administration. Globe study demonstrated Telbivudine had more excellent antiviral potency than Lamivudine, which was also comparable to or higher than Entecavir or Tenofovir. Nevertheless, the choice of treatment drugs can be limited due to the mutation rate of 25% for 2 years. However, the analysis of Globe study results showed that 2-year treatment progress was very good in patient who showed virologic response at 24 weeks after the initiation of treatment and that high antiviral potency and low mutation rate were observed when the Telbivudine roadmap strategy (in the event that virologic response is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done) recently implemented and announced in 2011 Asian Pacific Association for the Study of the Liver (APASL) was applied. However, the study was single arm study, which restricted the comparison between Entecavir and Tenofovir monotherapy groups. Therefore, this study intends to compare the anti-viral effect and mutation rate between Entecavir 0.5mg monotherapy group and Telbivudine roadmap strategy group in patients with HBeAg-positive chronic hepatitis B through a randomized study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B

NCT01595685

Chronic Viral Hepatitis B Without Delta-agent

COMPLETED PHASE3

A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)

NCT00651209

Hepatitis B, Chronic

COMPLETED PHASE4

Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B

NCT00412529

Hepatitis B Chronic Hepatitis B

COMPLETED PHASE3

Efficacy Study of Telbivudine in Chronic Hepatitis B Patients

NCT01958229

Chronic Hepatitis B Roadmap Concept in Chronic Hepatitis B Treatment 24-week PCR Negativity of Telbivudine +2 more

COMPLETED

Study of Telbivudine in Chronic Hepatitis B

NCT00970216

Chronic Hepatitis B

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

104 treatment-naïve patients with HBeAg-positive chronic hepatitis B who fulfill the inclusion criteria will be randomized in a 1:1 ratio to receive either Telbivudine 600mg monotherapy or Entecavir monotherapy with stratification before randomization according to presence of cirrhosis. For Telbivudine group, Telbivudine monotherapy or Tenofovir combined therapy will be done according to virologic response at 24 weeks and the primary study will be completed at Week 48 and treatment response will be analyzed. The treatment will be extended to Week 96 and the secondary analysis will be performed then.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Telbivudine-Tenofovir roadmap

Group Type EXPERIMENTAL

Telbivudine

Intervention Type DRUG

If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done

Intervention Type DRUG

Entecavir

Maintain the entecavir through the study period

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sebivo Viread Baraclude

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, at least 18 years of age
* Documented CHB defined by HBsAg or HBeAg positive at least 6 month prior
* HBsAg positive at screening visit
* HBeAg positive and Anti-HBe negative at screening visit
* Serum HBV DNA 20,000\~200,000,000 IU/mL as determined by Realtime PCR at screening visit
* Serum ALT 80\~400 IU/mL at screening visit
* Patient is willing and able to comply with the study drug regimen and all other study requirements
* Patient is willing and able to provide written informed consent to participate in the study

Exclusion Criteria

* Patient has received interferon, pegylated interferon, nucleoside or nucleotide drugs at any time
* Patient is co-infected with HCV, HDV, or HIV
* Patient with Child Pugh B or C (Child Pugh score ≥ 7)
* Patient has a history of or clinical signs/symptoms of hepatic decompensation such as ascites, esophageal variceal bleeding, hepatic encephalopathy
* Patient has any of the following laboratory values at screening visit:
* Hemoglobin \<10 g/dL
* Absolute neutrophil count (ANC) \<1,500/mm3
* Platelet count \<70,000/mm3
* Patient has a history of clinical and laboratory evidence of chronic renal insufficiency defined as an estimated serum creatinine clearance \< 50 mL/min using the MDRD formula at screening visit
* Patient is pregnant or breastfeeding
* Patient with currently abusing illegal drugs or alcohol sufficient
* Patient has organ transplantation
* History of any other acute or chronic medical condition that in the opinion of the investigator would make the patient unsuitable for inclusion into the study
* Patient has one or more additional known primary or secondary causes of liver disease, other than CHB, including steatohepatitis and autoimmune hepatitis
* Patient, if AFP is \>50ng/mL at screening visit, has image findings suggestive of HCC at Liver CT or Liver MRI
* Patient with hypersensitivity for study drug

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No